Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Revolutionizing the Approach to Spine Surgery We are more than a medical technolo...
Revolutionizing the Approach to Spine Surgery ...
Ligand is a biopharmaceutical company focused on developing or acquiring technolog...
Ligand is a biopharmaceutical company focused o...
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The C...
BioLineRx is a clinical-stage biopharmaceutical...
Artelo Biosciences is a biopharmaceutical company dedicated to applying true bioph...
Artelo Biosciences is a biopharmaceutical compa...
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using ...
Constellation Pharmaceuticals is a clinical-sta...
Join the National Investor Network and get the latest information with your interests in mind.